An observational study in Peripheral Arterial Disease, Critical Limb Ischemia and Frailty, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by University of Leicester · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · United Kingdom.
Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2019, is one of 11 observational ones, and was the 10th registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom are open now. Recruiting first, the newest first:
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 65+ · Healthy volunteers
Cardiovascular and Interventional Radiological Society of Europe · Sites in United Kingdom
Ages 18+
Cardiovascular and Interventional Radiological Society of Europe · Sites in United Kingdom
Ages 18+
University of Edinburgh · Sites in United Kingdom
Ages 18+
University of Manchester · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2019.
This study's planned enrollment of 420 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 49 across the 12 interventional studies, 250 across the 11 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
University of Leicester has 1 study filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07529886Guy's and St Thomas' NHS Foundation TrustSymptoms of Anxiety and/or Depression and SDM in Older Patients With CLTI | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Single-centre prospective cohort study of patients presenting with severe limb ischaemia (SLI). The primary outcome measure will be 12 month major amputation rate. A historical cohort of patients identified retrospectively will be the comparitor group used to assess the impact of a newly-established rapid-access limb salvage clinic.
Primary aim:
Secondary aims:
Severe limb ischaemia (SLI) is the end-stage of peripheral arterial occlusive disease (PAOD) whereby the viability of the limb is threatened due to the degree of arterial disease and subsequent ischaemia in the peripheral tissues. It is defined as ischaemic rest pain (or night pain) and/or ulceration or gangrene in the affected limb(s) for a minimum of two weeks attributed to confirmed PAOD. Treatment includes open surgical and endovascular revascularisation, with or without surgical debridement of affected tissues, amputation of toes and drainage of sepsis. In some patients revascularisation is not possible or fails resulting in the person requiring a major lower limb amputation.
Over 4000 major lower limb amputations per year were undertaken in England alone between 2003 and 2013 and a diabetes-related major lower limb amputation is performed every 30 seconds world-wide. As many as 25% of people with SLI will undergo a major lower limb amputation in the first year after presentation. Amputation negatively affects quality of life due to its negative impact on mobility, independence and ability to carry out activities of daily living.
This single-centre prospective cohort study will investigate the amputation rate at one year in patients presenting with SLI and compare this to a retrospectively identified historical cohort. This study will also investigate the prevelance and degree of frailty, cognitive impairment, and cardiac disease (detected by cardiac magnetic resonance imaging (MRI)), as well as establish a biobank for future biomarker analyses. The role of frailty and cognitive assessments, cardiac MRI and biomarker analysis in risk-stratifying patients with SLI will also be investigated.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
This study's planned enrollment of 420 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Browse Chronic Limb-Threatening Ischemia studies →University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
As representative a sample of patients presenting to the Leicester Vascular Institute with SLI during the study period as possible. All patients presenting with SLI within the age criteria will be eligible and personal consultee consent will allow recruitment even of those patients lacking capacity to consent.
PRIMARY COHORT
Inclusion Criteria:
Exclusion Criteria:
FRAILTY \& COGNITIVE ADDITIONAL ASSESSMENTS
Inclusion criteria:
Exclusion criteria:
CARDIAC MRI ADDITIONAL ASSESSMENTS
Inclusion criteria:
Exclusion criteria:
BIOMARKERS ADDITIONAL ASSESSMENTS
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Any patient presenting to the Leicester Vascular Institute with SLI during the 2 year recruitment period (minimum 420 patients).
Any patient recruited to the primary cohort aged ≥65 years and undergoing an intervention for SLI (minimum 150 patients, target 210 patients).
Any patient recruited to the primary cohort, with capacity to consent and undergoing an intervention for SLI (minimum 100 patients).
Any patient recruited to the primary cohort and undergoing an intervention for SLI (no target recruitment set).
Retrospectively identified cohort of patients presenting to the study site with SLI between 2013 -15 (target 420).
12 month amputation rate
Proportion of patients undergoing major lower limb amputation
Time frame: 12 months post recruitment
Amputation free survival
Composite outcome measure of death or amputation
Time frame: ≥12 months post recruitment
All-cause mortality
Death from any cause
Time frame: ≥12 months
Quality of life
Quality of life as measured by the Vascular Quality of Life questionnaire (VascuQoL) * 25 item questionnaire, score 1-7 for each item, higher score = better quality of life * Domains: activities (8 items), symptoms (4 items), pain (4 items), social (2 items) and emotional (7 items); each scored 1-7 (total of domain item scores/number of items) * Overall score 1-7 (total item score/25)
Time frame: 12 and 24 months post recruitment
Disability
Level of disability as measured by the Barthel Index - Score 0-20; higher score = greater degree of functional independence/lower level of disability
Time frame: 12 and 24 months post recruitment
Clinical Frailty Scale
Prevalence and degree of frailty as measured by the Clinical Frailty Scale (CFS) * Score 1-9, higher score = greater degree of frailty * Results will also be reported dichotomised to frail (score ≥5) and non-frail (score ≤4)
Time frame: Baseline, 12 and 24 months
Anxiety & Depression
Prevalence and degree of anxiety and depression as measured by the Hospital Anxiety and Depression Scale (HADS) * 14 item questionnaire; score 0-3 for each item, higher score = more severe anxiety/depression * Domains: Depression (7 items), Anxiety (7 items); each scored 0-21; 0-7 = normal, 8-10 = bordeline, 11-21 = abnormal (case).
Time frame: Baseline, 12 and 24 months
Cognitive impairment (Frailty & Cognitive additional assessments only)
Prevalence of cognitive impairment as detected by the Montreal Cognitive Assessment (MoCA) * Score 0-30; highger score = greater level of cognitive function * Results will also be reported dichotomised to normal (score ≥24) and cognitive impairment (score ≤23)
Time frame: Baseline, 3 and 12 months
Post-operative delirium (Frailty & Cognitive additional assessments only)
Incidence of post-operative delirium as detected by the Single Question in Delirium (SQiD) +/- 4 A's Test for delirium (4AT)
Time frame: 24 and 72 hours post intervention
Prevalence of coronary artery disease (Cardiac MR additional assessments only)
Prevalence of coronary artery disease as detected by stress cardiac MRI
Time frame: Baseline
Incidence of peri-operative myocardial infarction (Cardiac MR additional assessments only)
Incidence of peri-operative myocardial infarction as detected by cardiac MRI
Time frame: 2-4 months post intervention
Edmonton Frail Scale (Frailty & Cognitive additional assessments only)
Prevalence and degree of frailty as measured by the Edmonton Frail Scale (EFS) * Score 0-17, 0-5 = not frail, 6-7 = vulnerable, 8-9 = mild frailty, 10-11 = moderate frailty, 12-17 = severe frailty * Results will also be reported dichotomised to frail (score ≥8) and non-frail (score ≤7)
Time frame: Baseline, 3 and 12 months
Plan to share: Undecided — Anonymised dataset will be available on request to the Chief Investigator (Prof Rob Sayers). The study protocol will be published in an open-access journal prior to completion of recruitment.
Started May 2019 (actual). Primary completion is estimated for May 2022, 35 months after the start.
Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 35 months is close to that.
Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →